
Nathan explains why a TETON-2 post hoc analysis of recurrent events, 126 vs 161 with placebo, supports continuing inhaled treprostinil after progression.

Steven D. Nathan, MD, is the director of the Advanced Lung Disease Program and medical director of the lung transplant program at Inova Fairfax Hospital

Nathan explains why a TETON-2 post hoc analysis of recurrent events, 126 vs 161 with placebo, supports continuing inhaled treprostinil after progression.

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Treprostinil significantly slowed FVC decline and reduced clinical worsening events over 52 weeks in patients with IPF.

Steven D. Nathan, MD, FCCP, and Fernando J. Martinez, MD, MS, share clinical pearls and advice for the management of IPF.

Expert pulmonologists comment on emerging therapies in the pipeline for the treatment of IPF.

Fernando J. Martinez, MD, MS, and Steven D. Nathan, MD, FCCP, share their personal experiences using pirfenidone and nintedanib in clinical practice and discuss the role of managing comorbidities for the treatment of IPF.

Experts in pulmonology discuss the safety and efficacy of pirfenidone and nintedanib for the management of IPF.

Drs Fernando J. Martinez and Steven D. Nathan review the goals of therapy and the importance of non-pharmacological therapies for the management of IPF.

Steven D. Nathan, MD, FCCP, leads the discussion on the differential diagnosis of idiopathic pulmonary fibrosis (IPF).

Expert pulmonologists discuss the effect of early and late diagnosis on IPF disease management, as well as the importance of a multidisciplinary team approach to treatment.

Steven D. Nathan, MD, FCCP, provides an overview of idiopathic pulmonary fibrosis, including long-term disease complications and the effect on a patient’s quality of life.

December 21st 2021

December 21st 2021

December 21st 2021

December 21st 2021

December 21st 2021

November 11th 2021